Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $87.21: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company developing IMCIVREE (setmelanotide) as a precision medicine for rare MC4R pathway diseases including BBS and POMC/LEPR deficiencies. IMCIVREE is approved in the US, EU/UK, and Canada; the company... Read more
Sell if holding. Engine safety override at $87.21: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Rhythm Pharmaceuticals, Inc.
Latest news
- Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143 — benzinga May 7, 2026 positive
- Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results — benzinga May 6, 2026 positive
- RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137 — benzinga May 6, 2026 positive
- Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144 — benzinga May 6, 2026 positive
- Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call — benzinga May 5, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductIMCIVREE10-K Item 1A: 'Our operations to date have been primarily focused on developing and commercializing IMCIVREE (setmelanotide)'
Material Events(8-K, last 90d)
- 2026-04-03Item 5.02LOWRhythm Pharmaceuticals elected Kimberly J. Popovits to Board effective April 1, 2026; simultaneously Edward T. Mathers resigned from the Board (no disagreement cited). Routine board composition change.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $87.21: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $81.11. Score 5.1/10, moderate confidence.
Take-profit target: $124.38 (+42.6% upside). Prior stop was $81.11. Stop-loss: $81.11.
Concentration risk — Product: IMCIVREE; Quality below floor (3.5 < 4.0); Value-trap signals (3/5): Margin compression (op margin -50.1%), High leverage (D/E 6.1), Material insider selling (5 sells, 0.17% of cap).
Rhythm Pharmaceuticals, Inc. trades at a P/E of N/A (forward -76.7). TrendMatrix value score: 5.4/10. Verdict: Sell.
22 analysts cover RYTM with a consensus score of 4.3/5. Average price target: $138.
What does Rhythm Pharmaceuticals, Inc. do?Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company developing IMCIVREE (setmelanotide) as a...
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company developing IMCIVREE (setmelanotide) as a precision medicine for rare MC4R pathway diseases including BBS and POMC/LEPR deficiencies. IMCIVREE is approved in the US, EU/UK, and Canada; the company generated ~$422.5M cumulative revenue from product sales and had 414 employees as of February 2026.